Clinical Trial Update: Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and efficacy of [18F]PSMA-1007 injection for suspected persistent or recurrent prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-PSMA-1007 (PSMA-1007 radiotracer)

Snippet

Sponsor: Centre for Probe Development and Commercialization | Conditions: Prostate Cancer Recurrent, Recurrent Prostate Cancer | Phase 3 | Status: COMPLETED